Taysha Gene Therapies Presents Preclinical Data On TSHA-102 For Rett Syndrome Demonstrating Cellular Regulation Of MeCP2 Expression In Key Mouse Models At The American Society Of Gene And Cell Therapy 26th Annual Meeting
Portfolio Pulse from Happy Mohamed
Taysha Gene Therapies presents preclinical data on TSHA-102 for Rett syndrome, demonstrating cellular regulation of MeCP2 expression in key mouse models. The data suggests TSHA-102, engineered with miRARE technology, avoided toxic overexpression of MeCP2. Dosing of the first adult patient in the Phase 1/2 REVEAL trial is expected in Q2 2023.
May 19, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Taysha Gene Therapies' TSHA-102 shows promising preclinical data for Rett syndrome treatment, avoiding toxic overexpression of MeCP2. First adult patient dosing in Phase 1/2 trial expected in Q2 2023.
The positive preclinical data on TSHA-102 for Rett syndrome demonstrates the potential of the miRARE technology to enable safe expression levels of MeCP2. This could lead to increased investor interest and a positive short-term impact on Taysha Gene Therapies' stock price. The dosing of the first adult patient in the Phase 1/2 REVEAL trial is expected in Q2 2023, which could further boost investor confidence.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100